Compare OTLK & NXDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTLK | NXDT |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 259.1M |
| IPO Year | 2016 | N/A |
| Metric | OTLK | NXDT |
|---|---|---|
| Price | $1.41 | $5.62 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 11.8M | 154.3K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ 0.99 |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | ★ N/A | $5.68 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $2.55 |
| 52 Week High | $3.39 | $5.95 |
| Indicator | OTLK | NXDT |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 63.88 |
| Support Level | $1.21 | $4.43 |
| Resistance Level | $1.54 | N/A |
| Average True Range (ATR) | 0.18 | 0.25 |
| MACD | -0.06 | 0.06 |
| Stochastic Oscillator | 17.54 | 71.93 |
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.